Zhitong Finance App News, Bibet (688759.SH) issued a stock price change announcement stating that the company is a biomedical company using the fifth set of listing standards. The company has only 1 product approved for listing, 1 product is in phase III clinical trials, 1 product has been approved for phase III clinical trials, 5 products are in phase I clinical trials, and other products are still in the pre-clinical research stage. The company is currently unprofitable and has accumulated uncompensated losses. It is expected that large-scale continuous investment in R&D will be required in the future. The biomedical industry is notable for its long R&D cycle, large capital investment, and high uncertainty about success. From early discovery to final commercialization, new drugs need to go through multiple stages such as preclinical research, clinical development, regulatory approval, production and marketing, which are fraught with many uncertainties.

Zhitongcaijing · 4d ago
Zhitong Finance App News, Bibet (688759.SH) issued a stock price change announcement stating that the company is a biomedical company using the fifth set of listing standards. The company has only 1 product approved for listing, 1 product is in phase III clinical trials, 1 product has been approved for phase III clinical trials, 5 products are in phase I clinical trials, and other products are still in the pre-clinical research stage. The company is currently unprofitable and has accumulated uncompensated losses. It is expected that large-scale continuous investment in R&D will be required in the future. The biomedical industry is notable for its long R&D cycle, large capital investment, and high uncertainty about success. From early discovery to final commercialization, new drugs need to go through multiple stages such as preclinical research, clinical development, regulatory approval, production and marketing, which are fraught with many uncertainties.